ArticleGenome medicine2010
Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics.
Article in Genome medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma.Clinical epigenetics · 2022Article
- miR-21-5p/PRKCE axis implicated in immune infiltration and poor prognosis of kidney renal clear cell carcinoma.Frontiers in genetics · 2022Article
- DNA Methylation inCancers · 2021Article
- MMP25-AS1/hsa-miR-10a-5p/SERPINE1 axis as a novel prognostic biomarker associated with immune cell infiltration in KIRC.Molecular therapy oncolytics · 2021Article
- Epigenetic Biomarkers of Renal Cell Carcinoma for Liquid Biopsy Tests.International journal of molecular sciences · 2021Review
- The prognostic value and immunological role of the small mother against decapentaplegic proteins in kidney renal clear cell carcinoma.Translational cancer research · 2021Article
- Identification of Two Immune Related Genes Correlated With Aberrant Methylations as Prognosis Signatures for Renal Clear Cell Carcinoma.Frontiers in genetics · 2021Article
- Promising Epigenetic Biomarkers Associated With Cancer-Associated-Fibroblasts for Progression of Kidney Renal Clear Cell Carcinoma.Frontiers in genetics · 2021Article
- Combining epigenetic and clinicopathological variables improves specificity in prognostic prediction in clear cell renal cell carcinoma.Journal of translational medicine · 2020Article
- Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma.Molecular genetics and genomics : MGG · 2020Article
- Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.Genome medicine · 2020Article
- Clinical data analysis reveals the role of OGR1 (GPR68) in head and neck squamous cancer.Animal models and experimental medicine · 2020Article
- Integrative Analysis of Sirtuins and Their Prognostic Significance in Clear Cell Renal Cell Carcinoma.Frontiers in oncology · 2020Article
- DNA methylation of CRB3 is a prognostic biomarker in clear cell renal cell carcinoma.Molecular biology reports · 2019Article
- DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.BMC cancer · 2019Article
- Epigenetics in renal cell cancer: mechanisms and clinical applications.Nature reviews. Urology · 2018Review
- Targeting DNA Methyltranferases in Urological Tumors.Frontiers in pharmacology · 2018Review
- Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2017Review
- Network of microRNA, transcription factors, target genes and host genes in human mesothelioma.Experimental and therapeutic medicine · 2017Article
- Epigenetic inactivation of HOXA11, a novel functional tumor suppressor for renal cell carcinoma, is associated with RCC TNM classification.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant DNA methylation, in particular promoter hypermethylation and transcriptional silencing of tumor suppressor genes, has an important role in the development of many human cancers, including renal cell carcinoma (RCC). Indeed, apart from mutations in the well studied von Hippel-Lindau gene (VHL), the mutation frequency rates of known tumor suppressor genes in RCC are generally low, but the number of genes found to show frequent inactivation by promoter methylation in RCC continues to grow. Here, we review the genes identified as epigenetically silenced in RCC and their relationship to pathways of tumor development. Increased understanding of RCC epigenetics provides new insights into the molecular pathogenesis of RCC and opportunities for developing novel strategies for the diagnosis, prognosis and management of RCC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.